

References

1. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. *J Immunother Cancer*. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. PMID: 29907163; PMCID: PMC6003181.
2. Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020. PMID: 35390769.
3. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. *Nat Rev Immunol*. 2022 Feb;22(2):85-96. doi: 10.1038/s41577-021-00547-6. Epub 2021 May 17. PMID: 34002066; PMCID: PMC8127450.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.